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This report is based upon postnatal follow up with women to determine gaps in standards of care for women 
in Bangladesh with hypertensive disorders in pregnancy, and to assess any pattern of morbidities among 
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Hypertensive disorders in pregnancy (HDPs) (BP ≥140 mmHg/≥90 mmHg) are the second leading cause of 
maternal mortality in Bangladesh, responsible for 24 percent of maternal deaths. Various factors, such as 
lack of health care provider capacities for detecting, preventing, and managing pre-eclampsia and 
eclampsia (PE/E), late referrals, late (or lack of) antenatal care (ANC), and poor awareness of PE/E, are 
factors in most of these avoidable deaths. While some information was available on the prenatal and 
postnatal periods, there was an evidence gap in information after delivery through the first year postnatal, 
and beyond.  
For most women with HDP in Bangladesh, care largely stops after delivery, yet studies suggest that 
complications associated with HDP continue throughout the immediate postnatal period and longer. While 
standard international guidelines recommend lifelong care and monitoring, at a minimum close monitoring 
for at least six months to one year after delivery is recommended. In this prospective cohort study, the 
Ending Eclampsia project recruited married women ages 15 to 49 years (after their informed consent) with 
HDP, along with their infants, around the time of delivery and prospectively followed them for up to one 
year to evaluate their care, assess their health statuses, and identify any pattern of morbidities through 
record reviews, interviews, medical checks and laboratory tests.  
This study was conducted in the Eclampsia Unit of a tertiary care hospital in Dhaka. All clients admitted to 
the study in its first six months were enrolled for a record review, and consenting women were enrolled for 
follow up at their ninth week, sixth month, and 12th month postnatal. A trained Research Assistant with the 
help of nurses, midwives, or medical officers in the Obstetrics and Gynecology Department recruited study 
participants, reviewed their treatment records, and conducted a survey guided by a standardized 
questionnaire. Medical check ups of women and their infants were conducted by an obstetrician and a 
pediatrician, respectively, and laboratory tests were performed in a private reference laboratory. 
Among the 400 women with HDP enrolled for record reviews, 160 women consented to follow up, as 
estimated for the study. The number of women with HDPs who returned at their ninth week, sixth month, 
and 12th month following enrollment were 48 (30.0%), 26 (16.3%), and 32 (20.0%), respectively. For all 
record reviews, two fifths of women were under age 25, and more than 90 percent had some primary or 
further education, two fifths were primigravida (i.e. pregnant for the first time), and three quarters were 
admitted to the Eclampsia Unit at 34 or more weeks’ gestation. About 60 percent of infants weighed less 
than 2.5 kilograms (kg) at birth. The overall rate of early onset PE (at <34 weeks gestation) was 25.3 
percent, with no significant variations within the four HDP sub-types (chronic hypertension (HTN), 
gestational HTN, PE, eclampsia). The rate of pre-term delivery was extremely high, at 62.5 percent, with 
gross variations by HDP sub-type. The stillbirth rate was 15.3 percent, which also varied by HDP sub-type.  
Poor quality of care and poor documentation were evident. For example, while blood pressure (BP) was 
measured for 89 percent of the women on their first day postnatal, and documented, by the fifth day only 
14 percent of women had BP measured and documented. While all women with HDPs should continue anti-
hypertensive medication until their BP is well-controlled, about 30 percent of women who had PE with BP 
≥150/100 mmHg were on no anti-hypertensive drugs during their first week postnatal. Women whose data 
were available from all four data collection points (n=21) reveal that a number of them remained 
hypertensive one year postnatal. Similarly, while nephrological evaluation requires attention equal to BP 
measurement, there was limited documentation, and evaluation progressively declined from the first 
through the fifth day. Findings show that 10.5 percent of women with HDP had significant albumin in their 




Almost all women who remained hypertensive were offered medical reviews at two weeks postpartum, and 
at six to eight weeks after discharge, however, documented in the record reviews. Record reviews also show 
that not all women were documented or evaluated for metabolic functions, though. Women observed and 
tested for metabolic functions over a year showed considerable metabolic disfunctions since delivery: 6.3 
percent of those women had persistent high creatinine levels, 12.5 percent had elevated aspirate 
transferase, 34.4 percent had elevated alanine transferase, and many had dyslipidemia.  
The following conclusions and recommendations emerged from this study, to help health care providers, 
public health experts, policy decision-makers, health administrators, and developmental partners in 
Bangladesh provide better services to women with HDPs: 
• Gaps in PNC are evident including clinical assessment, laboratory evaluations, follow up, and 
counseling. Standard operating procedures (SOPs) for PNC should be developed, including 
management of women with HDPs, and made widely available to obstetricians, nurses, and midwives 
who provide services to pregnant women. 
• Health care challenges need to be addressed in the postnatal period. Women with pregnancy and 
postnatal complications, and their families, require specific, relevant information to enable their 
awareness and understanding of their potential consequences to their future health, and why they 
should attend follow up consultations. Women with pregnancy and postnatal complications are barely 
counseled about their potential effects on their future health, however. Health care facilities must find 
ways to ensure women return for follow up care, and increase efficiencies so service providers can 
provide effective counseling. 
• Blood pressure is either not routinely measured, or measured but not documented. Service providers 
who treat pregnant women should be aware of the importance of routine BP measurement, and 
continued monitoring in women after delivery, and its documentation. This continuous monitoring 
applies to urine albumin as well. 
• Service providers should all know that hypertension in women with HDP does not necessarily resolve 
after delivery. They must monitor all women with HDP until documented resolution of the hypertension, 
to avoid any further complications. Screening for development of metabolic syndromes after PE-
complicated pregnancies should be routine by service providers.  
• Early detection of HDP and careful management is essential: All pregnant women should be screened 
for PE after 20 weeks of pregnancy. 
• Pre-term delivery and low birth weight (LBW) infants were extremely common in this study. All women 
with HDP should be made aware of the necessity of hospital delivery with neonatal support.  
• Women who experienced HDPs were rushed or referred to Dhaka Medical College and Hospital from 
a number of districts surrounding Dhaka, which indicates inefficiencies or lack of capacity at lower 








Hypertensive disorders in pregnancy (HDP) are responsible for 70,000 maternal deaths globally, killing one 
woman every 11 minutes (Magee et al 2016). HDP is the second leading cause of maternal mortality in 
Bangladesh, according to the Bangladesh Maternal Mortality Survey 2017, with about 24 percent of the 
country’s maternal deaths caused by pre-eclampsia/eclampsia (PE/E) (Niport et al 2018), which affects 
women during pregnancy, childbirth, as well as postpartum. Factors such as lack of health care provider 
capacities to detect, prevent, and manage PE/E, late referrals of HDP clients, late attendance and lack of 
antenatal care (ANC) and awareness about PE/E among communities have been implicated as reasons for 
most of these avoidable deaths (Warren et al 2015).  
Ending Eclampsia baseline analyses of 12 Bangladesh sub-districts’ health care facilities’ readiness and 
providers’ competencies for detecting and managing HDP revealed gaps in care for women with HDP during 
the antenatal period (Warren et al 2015). One critical gap was information provided after childbirth, in the 
immediate postpartum period and thereafter. The United Kingdom’s National Institute for Clinical 
Excellence (NICE) guideline recommends frequent blood pressure (BP) measurement in the days after 
delivery, as peak BP occurs three to five days following delivery. Women who had gestational hypertension 
or PE should receive a comprehensive medical review six to eight weeks after delivery, with a discussion of 
their increased lifetime cardiovascular risk, anti-hypertensive treatment, and risk for future pregnancy (NICE 
2013, RCOG 2010). The NICE guideline also recommends stopping methyldopa within two days of delivery, 
as the drug has been associated with depression, which may exacerbate risk of postpartum depression 
(NICE 2013, Beilin et al 1977). In addition, some women with HDP who required no anti-hypertensive 
treatment during pregnancy may require it postnatally, and, in fact, about 45 percent of eclampsia occurs 
in the immediate postnatal period, mostly within the first four days, but may occur up to four weeks later, 
so meticulous BP surveillance after delivery is highly recommended (RCOG 2010, Firoz and Melnik 2011, 
NICE 2013). 
It has also been documented that about 25 percent of women with HDP, especially those with a severe 
condition, experience a deterioration of end-organ functions during puerperium (the 6 to 8 weeks after 
delivery, during which pregnancy changes return to baseline) (Deruelle et al 2006). PE early in pregnancy 
(<34 weeks of gestation), presenting in a severe form, or persistence of proteinuria more than three to six 
months after delivery suggests possible chronic hypertension or renal disease. Women with PE are also at 
increased risk for venous thromboembolism in the postnatal period, and those women should receive 
thromboembolic prophylaxis after delivery until they are fully mobile, usually within four to six weeks (RCOG 
2015). Similarly, women with pre-term PE and gestational hypertension have been found to develop 
persistent cardiovascular impairment one year after delivery (Melchiorre et al 2011), including other 
chronic diseases such as chronic hypertension, stroke, renal disease, diabetes mellitus, and ischemic heart 
disease. Infants born to women with HDP also require special attention in the immediate postnatal period 
due to a combination of short- and long term risks. Standard international guidelines recommend lifelong 
care and monitoring, or a minimum of care and monitoring for six months to one year after delivery. Studies 
suggest that complications associated with HDP continue in the immediate postnatal period and longer 
(NICE 2011). 
Currently there is no locally available guideline in Bangladesh that directs postnatal care (PNC) for women 
with HDP, and even WHO’s PE prevention and management guideline does not include the postnatal period. 
Nothing much is known of the kind and contents of care (if any at all) women with HDP receive, and of 
associated morbidities after delivery in Bangladesh. It is assumed that care for women with HDP in 




In this prognostic study, the Ending Eclampsia project recruited women ages 15 to 49 years with HDP, 
following their informed consent, as well as their infants, around the time of their deliveries, and 
prospectively followed them for up to one year, to evaluate their care, assess their health statuses, and 
identify any morbidity patterns. This gap analysis not only provides insights into the quality of care women 
with HDP received postnatally, as well as their health statuses and morbidity patterns, including their 
infants, but will improve policy-makers’ and program managers’ understanding of actual patient care and 
inform the design of interventions to improve the future care of women with HDPs. 
Methodology 
Study Design 
This was a prospective cohort study of one year involving married pregnant women 15 to 49 years of age 
diagnosed with HDPs, and included their infants, who attended a tertiary care hospital in Bangladesh—the 
Eclampsia Unit of Dhaka Medical College and Hospital (DMCH). The study has no comparison group. A 
woman with any diagnosed HDP (chronic hypertension, gestational hypertension, PE/E) who was admitted 
to the eclampsia unit of DMCH’s Ob/Gyn Department for complications management near the time of her 
delivery was eligible to be a study participant.  
Women suffering from HDPs were selected for participation on a volunteer basis, with the selection criteria 
of: any married woman age 15 to 49 with any HDP admitted to the eclampsia unit willing to provide her 
informed consent. After informing each woman with HDP of the study’s purpose and its objectives, women 
willing to participate in the study were asked for their written informed consent, for current and subsequent 
interviews, standard medical examinations and laboratory tests (see Appendix), and subsequent interviews. 
Those willing to participate were enrolled, their records were reviewed, and medical examinations and 
laboratory tests were conducted, following a baseline interview. HDP participants were enrolled over a 
period of six months. A trained Research Assistant, with the help of nurses, midwives, or medical officers 
in the department, recruited study participants, reviewed their treatment records, and conducted a survey 
prescribed by a standardized questionnaire. Standard medical examinations of women and their infants 
were by an obstetrician and a pediatrician, respectively. 
All eligible pregnant women with HDPs admitted to the eclampsia unit during the enrollment period were 
selected for record reviews. Only those who provided informed consent to participate in the study were 
selected for subsequent follow up, including routine physical and medical examinations, laboratory tests, 
and an interview dictated by a standardized questionnaire. Physical examinations and clinical information 
for the infants of enrolled women were also conducted at baseline and at subsequent visits. Women and 
their infants were assessed prospectively at nine weeks, six months, and one year, when the clinical and 
laboratory assessments conducted at baseline were repeated.  
This study gathered information on the content and quality of care these women received for one year 
postnatal through individual interviews during each follow up visit.  
The study commenced in November 2017, and the last client to be enrolled exited the study on June 30, 
2019. To improve the follow up rate, women were encouraged (if they wished) to provide their mobile phone 










The study was conducted in the maternity and eclampsia units of Dhaka Medical College and Hospital 
(DMCH). This tertiary facility is a high volume site with well-functioning ANC clinics, delivery rooms, PNC 
clinics, but with a weak data management system. This facility not only serves women in and around Dhaka 
district, but from other parts of the country. We collaborated closely with DMCH’s Obstetrical and 
Gynecological (Ob/Gyn) department to recruit and follow enrolled participants. Challenges prevented the 
hospital laboratory from performing all required investigations, so laboratory tests were instead performed 




around the time of delivery/labor 
(Maternity ward) and collection of baseline 
information  
Senior Consultant at the Maternity Ward 
assisted by Research Assistant 
First Follow Up at Ninth Week 
Second Follow Up at Sixth Month 
Senior Consultant at the Maternity Ward 
assisted by Research Assistant 
Senior Consultant at the Maternity Ward 
assisted by Research Assistant 
• Review clinical records, discharge certificate 
• Medical checks, lab checks 
• Follow up interview on quality of care 
• Review any treatment document/prescription 
received elsewhere outside the Medical College 
• Medical checks, lab checks 
• Follow up interview on quality of care 
Third Follow Up at 12th Month 
• Review any treatment document/prescription 
received elsewhere outside of the Medical College 
• Medical checks, lab checks 
• Follow up interview on quality of care 
Senior Consultant at the Maternity Ward 
assisted by Research Assistant 
Participant Recruitment 
Senior Consultant at the Maternity Ward 





The study was designed to recruit and follow as many women as possible within a six month enrollment 
period. Given a 10 percent of incidence of HDP, with 95 percent confidence interval and five percent 
precision, it was estimated that 138 women were required for participation in this study. Considering a 
potential 20 percent non-response rate, 166 women were needed for statistical analysis. Ultimately 160 
women with HDP (and their infants) were recruited for the study, to be followed for one year, with their full 
informed consent. Record reviews were conducted with all 400 women with HDP admitted to the eclampsia 
unit during the six month enrollment period. 
Operational Definition of Hypertensive Disorders in Pregnancy 
HDP refers to a group of medical conditions in pregnancy characterized by the presence of high blood 
pressure (BP≥140/≥90mmHg). A woman was considered hypertensive if her index pregnancy was 
complicated by any of the following hypertensive conditions: 
• Chronic hypertension in pregnancy, which is any hypertension (BP≥140/≥90mmHg) present before 
pregnancy or diagnosed before 20 weeks’ gestation; 
• Gestational hypertension, any hypertension (BP≥140/≥90mmHg) appearing for the first time after the 
20th week of pregnancy; 
• Pre-eclampsia and eclampsia, which are any hypertension (BP≥140/≥90mmHg) appearing for the 
first time after 20 weeks of pregnancy and associated with significant protein in urine; if a client with 
PE develops convulsion in the absence of any neurological cause, it is seen as eclampsia; and 
• Significant protein in urine (proteinuria), with protein excretion in urine of ≥2++, measured using urine 
dipsticks. 
Study Objectives 
The overall goal of this study is to identify service delivery gaps and patterns of morbidities associated with 
HDP within one year postnatal. The project’s learning objectives and research questions are: 
• What care do women with HDPs typically receive (clinical and biochemically), following delivery 
(immediately postpartum and extended postpartum period of up to one year) compared to 
international guidelines, as benchmarks? 
• What care do infants of women with HDP typically receive following delivery (immediately postpartum 
and extended postpartum period up to one year), compared to international guidelines, as 
benchmarks? 
• What are the experiences, expectations, and satisfaction with services of women with HDPs during 







Background Characteristics of Women and Infants 
Four hundred women with HDP, both in or near delivery, were admitted to DMCH’s eclampsia unit from 
November 2017 to April 2018. These 400 women’s, and their infants’, baseline clinical and laboratory 
information were reviewed, through record reviews, after receiving informed consent from the women. 
Among these 400 women with HDP, 160 consented to participate in follow up activities, and the proportion 
of women who returned at nine weeks, six months, and one year were 30.0 percent, 16.3 percent, and 
20.0 percent, respectively. The proportions of infants brought at nine weeks, six months, and one year for 
check ups were lower principally due to neonatal deaths, while some were not brought in because of 
sickness on the date of follow up (Table 1). 
Table 1: Distribution of postnatal women with Hypertensive Disorders in Pregnancy and their infants 
Type of data Women (n) Infants (n) 
Women and infant records reviewed, baseline data collected 400 400 
Women consented to be followed up        160 
Women and infants showed up at 9 weeks 48 (30.0%) 35 (21.8%) 
Women and infants showed up at 6 months 26 (16.3%) 17 (10.6%) 
Women and infants showed up at 12 months 32 (20%) 25 (15.6%) 
While most women were from Dhaka district, women from other parts of the country also sought emergency 
services at the hospital or were referred from other districts. The women came from 28 districts total, while 
47 percent were from Dhaka district.  
Figure 1: Distribution of women with Hypertensive Disorders in Pregnancy admitted, by residence 
 
District Legend: 
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Table 2 describes the socio-economic characteristics and birth outcomes of the 400 HDP enrolled women, 
with two fifths of the women under age 25, more than 90 percent with at some primary or further education, 
two fifths primigravida, and three quarters admitted to the Eclampsia Unit at 34 or more weeks of gestation. 
About 60 percent of infants had birth weight of less than 2.5 kg.  
Table 2:  Demographic and medical characteristics of women and infants (record review)  
Characteristic Number (n=400) Percentage (%) 
Women’s ages at baseline (year) 
<20 53 13.3 
20-24 105 26.3 
25-29 121 30.2 
30-34 77 19.2 
>34 44 11.0 
Median age 25 years 
Education 
No education 37 9.2 
Primary 173 43.2 
Secondary 151 37.8 
Higher secondary and above 39 9.8 
Parity 
Prime 161 40.3 
2– 3  188 47.0 
≥4 51 12.7 
Gestational age at enrolment (weeks) 
<34 101 25.3 
≥34 287 71.8 
Admitted in PNC  12 3.0 
Systolic BP at baseline (mmHg) 
<140 65 16.3 
140-159 117 29.3 
≥160 218 54.5 
Diastolic BP at baseline (mmHg) 
<90 32 8.0 
90-109 195 48.8 
≥110 173 43.2 
Urine proteinuria 
Nil 73 18.2 
Trace 49 12.2 
1+ 40 10.0 
2+ 59 14.8 
3+ 66 16.5 
4+ 113 28.3 
Birth weight (kg)                                                           (n=325)1 
<2.5 191 58.8 
2.5 – 3.5 119 36.6 
>3.5 15 4.6 
Birth outcome 
Alive 325 81.2 
Stillbirth 61 15.3 








Figure 2 shows that most women with HDP admitted to the hospital during labor and delivery had severe 
PE/E (66.7%), 22 percent experienced PE, nine percent had gestational hypertension, and the rest (3%) 
had chronic hypertension.  
Figure 2: Types of Hypertensive Disorder in Pregnancy at admission (n=400) 
 
“Preeclampsia is a heterogeneous disorder, progress in the understanding of this disorder would be 
assisted greatly if subtypes could be characterized. It is recommended to subdivide preeclampsia into early-
onset (EO-PE) disease (occurring at <34 weeks gestation) and late onset (LO-PE) disease (occurring at <34 
weeks gestation)” (Dadelszen et al 2003).  
Of the total 400 women with HDPs whose records were reviewed in this study, the overall EO-PE disease 
rate reported was 25.3 percent, with no significant variations among the four HDP sub-types. Of the total 
354 women with sub-type PE/E, 25.7 percent reported EO-PE, while the remaining 74.3 percent reported 
LO-PE. For HDP sub-type gestational hypertension, only 20.6 percent of women reported EO-PE, while 25 
percent of women reported of HDP sub-type chronic hypertension (Table 3, following page). 
Gestational age at birth is associated with pre-term delivery, growth restriction, LBW, stillbirth, and some 
long term chronic diseases (Neggers 2018). The American College of Obstetricians and Gynecologists 
defines “Infants born between 20 to 37 weeks of pregnancy are called ‘preterm’ or ‘premature’. Infants 
born before 28 completed weeks of pregnancy are considered extremely preterm” (WHO 2019, ACOG 
2019).  
In this study, the overall preterm/premature delivery rate was extremely high, at 62.5 percent, with 
variations among HDP sub-types, including women with gestational hypertension who delivered 
prematurely (47.1%) and women with severe PE/E (63.3%). The extremely pre-term or premature rate (<28 
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Table 3: Gestational profiles of women with Hypertensive Disorders in Pregnancy     





Gestational Age at Onset of HDP 
Chronic Hypertension 12 
<34 weeks 3 25.0  
≥34 weeks 9 75.0  
Pre-Eclampsia 87 
<34 weeks 22 25.3  
≥34 weeks 65 74.7  
Severe Pre-Eclampsia and Eclampsia 267 
<34 weeks 69 25.8  
≥34 weeks 198 74.2  
Gestational Hypertension 34 
<34 weeks 7 20.6  
≥34 weeks 27 79.4  
Gestational Age at Delivery 
Choric Hypertension 12 
<28 weeks - -  
28–36 weeks 7 58.3  
≥37 weeks 5 41.7  
Gestational Hypertension 34 
<28 weeks - -  
28–36 weeks 16 47.1  
≥37 weeks 18 52.9  
Pre-Eclampsia 87 
<28 weeks - -  
28–36 weeks 47 54.0  
≥37 weeks 40 46.0  
Severe Pre-Eclampsia and Eclampsia 267 
<28 weeks 11 4.3  
28–36 weeks 169 63.3  
≥37 weeks 87 32.6  
An infant's weight at birth is strongly associated with its mortality risk during the first year and, to a lesser 
degree, with developmental problems in childhood and risks of various diseases in adulthood (Wilcox 
2001). WHO defines low birth weight as less than 2.5 kg at birth, regardless of gestational age (WHO 2019). 
In this study, the proportion of low birth weight (<2.5 kg) infants was 58.8 percent among infants of women 
with HDP, ranging from 45.5 percent among infants of women with chronic hypertension to 64.5 percent 
among infants of women whose pregnancies were complicated by severe PE/E (Table 4, following page).  
The relative risk of fetal death is remarkably high among pregnancies diagnosed with PE in the pre-term 
period (Harmon et al 2015). In this study, the overall stillbirth rate among women with HDPs was 15.3 
percent, and varied by HDP sub-type, as shown in Table 3, with the highest rate among women with severe 
PE/E (18%). In this study, the early neonatal death rate was 3.5 percent, particularly among women with 





Table 4: Types of Hypertensive Disorders in Pregnancy, by outcome measures    





HDP categories and fetal weight (kg)                                                                                                      n=3252 
Chronic Hypertension 11 
<2.5 5 45.5  
2.5 – 3.5 6 54.6  
>3.5 - -  
Gestational Hypertension 32 
<2.5 15 46.9  
2.5 – 3.5 13 40.6  
>3.5 4 12.5  
Pre-Eclampsia 71 
<2.5 35 49.3  
2.5 – 3.5 28 39.4  
>3.5 8 11.3  
Severe Pre-Eclampsia and Eclampsia 211 
<2.5 136 64.5  
2.5 – 3.5 72 34.1  
>3.5 3 1.4  
HDP categories versus fetal outcomes 
Chronic Hypertension 12 
Alive  11 91.7  
Stillbirth 1 8.3  
Early neonatal death (<7 days postnatal) 0 0.0  
Gestational Hypertension 34 
Alive  32 94.1  
Stillbirth 2 5.9  
Early neonatal death (<7 days postnatal) 0 0.0  
Pre-Eclampsia 87 
Alive  71 81.6  
Stillbirth 10 11.5  
Early neonatal death (<7 days postnatal) 6 6.9  
Severe Pre-Eclampsia and Eclampsia 267 
Alive  211 79.0  
Stillbirth 48 18.0  
Early neonatal death (<7 days postnatal) 8 3.0  
Table 5 (on the following page) shows the pattern of hypertension severity among women who suffered 
from HDP during all four timeframes; this analysis was only for those women whose data were available for 
all four points of data collection (n=21). Findings show that hypertension persisted in some participants 
over a year, and also show that when hypertension persists beyond nine weeks, it tends to be mild to 
moderate (systolic ≥160mmHg, and or diastolic ≥110mmHg) for chronic hypertension, and mild to 










Table 5: Pattern of hypertension, severity and progression for all follow up periods,  

























































Data collection points and HDP progression  
Baseline Ninth week Sixth month 12th month 
n 






Hypertension 1 Moderate 1 Mild 1 Mild 1 Moderate 1 
Gestational 
Hypertension 
  3 Normal 3 Normal 3 Normal 3 
4 Mild 1 Severe 1 Mild 1 Mild 1 
Pre-Eclampsia    1 Normal 1 Normal 1 Normal 1 2 Mild 1 Mild 1 Severe 1 Moderate 1 
Severe PE/E  
      11 Normal 11 
5 Mild 3 Mild 2 Mild 1 Mild 1 
4 Moderate 1 Moderate 1 Moderate 1 Moderate 1 
5 Severe 10 Normal 11 Normal 1 Severe 1 
Total 21  21  21  21  21 
 
Quality of Postnatal Care for Women and Their Infants 
It is generally recommended that women with HDPs have their BP measured daily, for the first two days 
after birth, for chronic and gestational HTN, at least four times a day while a woman is a PE/E in-patient, 
and at least once between the third and fifth days following birth for all sub-types (NICE 2019). In this study, 
up to 89 percent of women with HDPs had their BP measured and documented on the first day, but the 
proportion progressively declined, as shown in Figure 3, and slightly increased on the day of discharge (fifth 
day postnatal).   
Figure 3: Percentage of women with Hypertensive Disorders in Pregnancy with BP measured  
































Similarly, up to 73 percent of women with HDPs had their urine checked and documented on the first day, 
but the proportion of women whose urine was checked and documented progressively declined thereafter, 
as shown in Figure 4, and increasing slightly on the day of discharge (sixth day postnatal). 
Figure 4: Percentage of women with Hypertensive Disorders in Pregnancy with urine checked  
and documented (from day 1 to day 5 and discharge day) (n=400) 
 
Table 6 shows levels of urine albumin among women with HDPs for each day surveyed (from day 1 to day 
5 and discharge day). While urine monitoring and documentation declined each day until day of discharge, 
still 11 percent of women had albumin in their urine at different levels (31% women had ≥2+ albumin) on 
day of discharge. 
Table 6: Percentage of women with Hypertensive Disorders in Pregnancy with urine checked  
and documented and level of urine albumin (From day 1 to discharge day) (n=400) 
Day of check 













Day 1 290 (72.5) 56 (19.3) 42 (14.5) 46 (15.9) 57 (19.7) 89 (30.7) 
Day 2 168 (42.0) 57 (33.9) 52 (30.9) 32 (19.1) 17 (10.1) 10 (5.9) 
Day 3 95 (23.8) 41 (43.2) 23 (24.2) 15 (15.8) 12 (12.6) 4 (4.2) 
Day 4 44 (11.0) 17 (38.6) 12 (27.3) 9 (20.5) 6 (13.6) - 
Day 5 31 (7.8) 13 (41.9) 7 (22.6) 4 (12.9) 7 (22.6) - 
Discharge day 42 (10.5) 21 (50.0) 8 (19.1) 7 (16.7) 5 (11.9) 1 (2.4) 
It is recommended that all women with HDPs should continue anti-hypertensive medication until their BP 
is well-controlled. A target BP level is systolic less than 140 mmHg and diastolic less than 90 mmHg (NICE 
2013). This study assessed the medical records of women with HDP to determine the extent of compliance 
with this recommendation. About 30 percent of women who experienced PE with moderate hypertension 
(BP≥150/100mmHg) were not on anti-hypertensive medication during their first week postnatal, and 23.9 
percent of women who experienced severe PE/E were not on anti-hypertensive drugs after giving birth 






























Figure 5: Percentage of women with moderate to severe hypertension (BP ≥150/100 mmHg)  
on anti-hypertensive treatment within a week of delivery, by type of HDP (N=277)3 
 
It is recommended that women suffering from HDPs receive continued care and counseling services for six 
to eight weeks following delivery. Four hundred admitted HDP women’s in-patient records reviews reveal 
poor quality of care and counseling, as well as poor documentation. Women with HDPs should receive 
information on danger signs (severe headache, blurred vision, nausea or vomiting, epigastric pain) when 
being discharged from a health facility, and only two records reviewed document this. No records document 
counseling on HDP risk for future pregnancy, nor on seeking early ANC or family planning (FP) counseling. 
No women’s files document thromboprophylaxis after delivery.  
While the quality of all other care and counseling were poor, almost all women who remained hypertensive 
were offered medical review at two weeks (99.3%) as well as six to eight weeks after discharge (98.5%), 
documented. Around one quarter (25.3%) of newborns received clinical and feeding assessments (23.5%) 
two to three days after birth. Only 11 percent of infants, however, are documented as being seen by a 
neonatologist (data not shown).  
Table 7: Percentage of women with HDPs who received appropriate care and counseling,  
from record reviews during hospitalization 
Counseling and services   
Received Total 
(n) Yes  n (%) 
No  
n (%) 
Received information on danger signs  
(severe headache, blurred vision, nausea, vomiting, epigastric pain) 2 (0.5) 398 (99.5) 400 
Offered medical check up 2 weeks after hospital discharge 397 (99.3) 3 (0.7) 400 
Offered medical review at 6 to 8 week postpartum visits 394 (98.5) 6 (1.5) 400 
Had PE/E and received thromboprophylaxis after delivery 0 (0.0) 400 (100.0) 400 
Had PE/E and offered urine protein estimation 6 to 8 weeks 
postpartum  0 (0.0) 388 (100.0) 388 
Clinical well-being of infant assessed daily for first 2 to 3 days  
after delivery 83 (25.3) 245 (74.7) 328 
Infant feeding assessed daily for 2 to 3 days after delivery 77 (23.5) 251 (76.5) 328 
Counseled on FP any time after delivery 1 (0.3) 399 (99.7) 400 
Counseled to attend ANC early in next pregnancy 0 (0.0) 400 (100.0) 400 
Counseled on risk of condition recurrence in subsequent pregnancy 0 (0.0) 400 (100.0) 400 
























Women’s Perceptions and Experiences with HDPs and Their Care  
Women (n=48) were asked about their perceptions and experiences of their quality of clinical care and 
counseling services at their nine week follow up visit. In general, the quality of their counseling was 
perceived as poor, as recalled by patients themselves (Table 8). 
Table 8: Women with HDP’s perceptions and experiences of care, at ninth week after delivery  
(women’s recall) 
Women’s perceptions and experiences of their care  
Received Total 
(n) Yes  (%) 
No  
(%) 
When you were told that you have one of the hypertensive conditions in 
pregnancy, did you understand what that meant? 4 (8.3) 44 (91.7) 48 
Did the health care provider find time to explain what the condition 
means and its implication for your health and that of your baby? 5 (10.4) 43 (89.6) 48 
Were you given the opportunity to ask questions for clarification? 6 (12.5) 42 (87.5) 48 
Is this the first time you have had this type condition in pregnancy?  40 (83.3) 8 (16.7) 48 
Has anyone in your family had this kind of condition in the past? 27 (56.3) 21 (43.8) 48 
Did you have any concerns when you were informed that you developed 
hypertension in pregnancy? 45 (93.8) 3 (6.3) 48 
Have you discussed this concern with your health care providers? 18 (40.0) 27 (60.0) 45 
Did you receive satisfactory feedback from your service providers? 12 (66.7) 6 (33.3) 18 
Do you think you have received the right care and information from your 
care providers during pregnancy with this condition?  35 (72.9) 13 (27.1) 48 
Did you suffer from any complication in this pregnancy as a result of this 
condition?  46 (95.8) 2 (4.2) 48 
Now that you have given birth, do you think that your caregivers have 
given you sufficient information about your future health  
after a pregnancy affected by hypertension? 
0 (0.0) 48 (100.0) 48 
Is knowing how this condition can be prevented in pregnancy something 
you are particularly interested in? 21 (43.7) 27 (56.3) 48 
If you are planning another baby in the future, have you been counseled 
on how to prevent this condition in future pregnancy? 1 (3.7) 26 (96.3) 27 
 
Clinical Courses of Women with Hypertensive Disorders in Pregnancy 
Six out of 21 women with various sub-types of HDP at baseline who attended all three follow ups over a 
year remained hypertensive over the entire period; yet some women’s BP rapidly dropped (Table 5).   
Women in the study who received health checks for a year were tested for metabolic functions. Table 9 
(following page) shows that numerous women’s metabolic functions deviated from normal. Meanwhile, 
Table 10 (page 18) shows that at baseline not all women were tested, or documented, for all required 
metabolic functions. For example, 67 (17%) of 400 women with HDPs were tested, or at least documented, 
for serum creatinine, and among those 77.6 percent had high levels. Similarly, 69.5 percent of 400 women 
with HDPs had proteinuria at baseline, and although in general these levels improved over time, 3.1 percent 
had abnormal protein excretion after a year, suggesting possible permanent kidney impairment (Table 9).   
Although also improving over time, 6.3 percent of women with HDP had persistent high creatinine levels for 
a year, suggesting further possible permanent kidney impairment. Similar patterns of persistent disparity 
were observed for glucose intolerance, liver enzymes (Alanine and Aspartate transaminases), serum 
cholesterol, and triglycerides (Table 9). These findings indicate that women with HDPs need long term 













(n=32) Laboratory reference value Total n (%) n (%) n (%) n (%) 
Persistent proteinuria 400 278 (69.5) 4 (8.3) 2 (7.6) 1 (3.1) Normal: Nil 
Glucose intolerance 
(mmol/L) 41 5 (12.2) 4 (8.3) 3(11.5) 5 (15.6) 
Normal :<7.8 
mmol/L 
High serum urea  
(mmol/L) 16 12 (75.0) 0 (0.0) 1 (3.9) 0 (0.0) 
Normal: 1.9-8.3 
mmol/L 
High serum creatinine 
(mmol/L) 67 52 (77.6) 33 (68.8) 9 (34.6) 2 (6.3) 
Normal: 53-120 
mmol/L 
Low platelets count  




transferase (U/L) 37 16 (43.2) 1 (2.1) 5 (19.2) 4 (12.5) 
Normal: up to 40 
U/L 
Elevated alanine 
transferase (U/L) 55 12 (21.8) 9 (18.8) 11 (42.3) 11 (34.4) 
Normal: up to 40 
U/L 
High total serum 
cholesterol (mg/dL) - - 18 (37.5) 10 (38.5) 9 (28.1) 
Normal: up to 200 
mg/dL 
High HDL cholesterol 
(mg/dL) - - 11 (23.9) 6 (23.1) 14 (43.8) 
Normal: up to 60 
mg/dL 
High LDL cholesterol 
(mg/dL) - - 17 (37.8) 9 (34.6) 6 (18.8) 
Normal up to 130 
mg/dL 
High serum triglycerides 
(mg/dL) - - 22 (45.8) 13 (50.0) 16 (50.0) 
Normal: up to 150 
mg/dL 
“=” not tested 
Table 10 provides the complication signs and symptoms of women with HDP for a year after delivery; 
women enrolled in the study who attended three follow up consultations were included in the analysis.  
The record review revealed that women with HDPs had a number of complications including headache 
(45%), blurred vision (22%), albuminuria (69.5%), and high BP (94.3%), among others. Those who 
continued follow up during the year following their delivery (n=32) had persistent residual complications 
including severe headache (56.3%), blurred vision (37.5%), albuminuria (12.5%), and high BP (37.5%). 
Table 10: Women with complications, their signs and symptoms, one year after delivery  
Complication Baseline (n=400) n (%) 
9 weeks (n=48) 
n (%) 
6 months (n=26) 
n (%) 
12 months (n=32) 
n (%) 
Loss of orientation - 0 5 (19.2) 3 (9.4) 
Severe headache 179 (45.0) 13 (27.1) 11 (42.3) 18 (56.3) 
Blurred vision 87 (22.0) 11 (22.9) 9 (34.6) 12 (37.5) 
Jaundice 13 (3.3) 1 (2.1) 0 0 
Chest pain - 1 (2.1) 0 0 
Abdominal pain 41 (10.3) 2 (4.2) 3 (11.5) 2 (6.3) 
Diminished urine output 6 (1.5) 0 0 0 
Urine albumin 278 (69.5) 6 (12.5) 7 (26.9) 4 (12.5) 






Clinical Courses of Infants 
The infants of women who attended all three PNC follow ups—at nine weeks, six months, and 12 months—
were also assessed. Table 11 lists the health and developmental parameters collected at the three points 
in time. At nine weeks, the mean weight of infants was 4.5 kg, with 1.3 kg standard deviation; at six months 
it was 7.5 kg, with 1.8 kg standard deviation, and at 12 months it was 9.5 kg, with 1.3 standard deviation. 
Stillbirth occurrence was 15.3 percent, and the neonatal death rate (<7 days) was 3.5 percent. 
Table 11: Changes in infants’ clinical developmental parameters, by data collection points in time  
Parameter 










Baby weight (kg) 4.5±1.3 7.5±1.8 9.5±1.3 
Baby length (cm) 49.2±13.6 62.7±4.1 71.5 ±7.3 
Occipitofrontal circumference (cm) 35.4±8.3 42.9±2.4 45.4±4.1 
Systolic BP (mmHg) 81.3±15.1 89.8±8.2 85.1±11.6 
Diastolic BP (mmHg) 51.1±11.4 56.8±6.6 54.0±8.9 
Heart rate (/min) 97.1±23.5 96.4±14.3 94.5 ±8.9 
Respiratory rate(/min) 40.1±9.2 43.1±7.1 36.2 ±9.2 
Outcomes   n=400 
Similarly, Table 12 lists the changes in infant developmental achievement for three data collection points—
at nine weeks, six months, and 12 months—among women and their infants who attended all three follow 
ups. For all parameters measured, most infants achieved their developmental milestones. 
Table 12: Percentage of infants’ developmental changes, by data collection points in time 
Parameter 







Social smile  34 (97.1) 17 (100.0) 25 (100.0) 
Neck control  34 (97.1) 16 (94.1) 25 (100.0) 
Sitting  - 9 (52.9) 25 (100.0) 
Crawling  - 2 (11.8) 25 (100.0) 
Standing with support  - 1 (5.8) 25 (100.0) 






This report results from a prospective cohort study of married women with HDP recruited around the time 
of their deliveries, who were then followed for 12 months, without any comparison group: 400 women with 
HDPs were admitted to Dhaka Medical College and Hospital, with the expectation of 166 recruited over six 
months for follow up—and 160 women consented. In reality, however, only 48 (30%) consenting women 
actually returned for follow up at nine weeks, while 26 (16.3%) returned at six months, and 32 (20%) 
returned at 12 months. Follow up attendance was poor even with repeated contacts with the women 
enrolled in the study. The reasons offered by women for their failure to return for follow up care included 
traffic jams, too much time necessary for travel, distance, lack of travel companions, and perceived 
absence of necessary because to feeling well, among others. The women were recruited at a high volume 
tertiary care hospital that serves patients in Dhaka district as well as from other parts of the country.  
As this was an empirical study with repeated, planned contacts for follow up resulting in a small proportion 
of women actually returning for care, real life scenarios may be even worse. Providers should counsel all 
women with HDPs on the importance of recommended follow ups, and patients should be adequately 
educated for their compliance with care for their future health. As the number of patients who completed 
three follow up visits was much lower than expected, these findings should be interpreted with caution. 
About half of women with HDP admitted to DMCH were from the Dhaka catchment area (47%). Although all 
of the women in the study live closer to a facility providing ANC, record reviews suggest poor ANC patterns 
among these women. A large number of women requiring emergency admission to a tertiary care facility 
for delivery complication management suggests poor ANC-seeking behaviors, along with poor quality ANC 
and PNC services at lower level facilities, and widespread lack of capacity for managing delivery 
complications with HDP. This indicates weaknesses within the health care system, particularly for pregnant 
women’s care. The Bangladesh Demographic and Health Survey 2017 revealed only 47 percent of women 
with WHO-recommended four or more ANC visits for their most recent birth (Niport et al 2018, WHO 2018), 
with poor PNC as well, where about half of women seek none after delivery (Niport et al 2018). 
Infant birthweight is strongly associated with mortality risk during the first year and, to a lesser degree, 
childhood developmental problems and risk of various diseases in adulthood (Wilcox 2001). Low birth-
weight is associated with poor cognitive development and chronic adult disease—type 2 diabetes, 
hypertension, and cardiovascular disease (Halbreich 2005). WHO defines LBW as less than 2.5 kg.  
Bangladesh has the highest incidence of LBW (22.6%) in Asia, with 80 percent of all LBW newborns born 
at term (IPHN 2017, Arifeen 1997, ACC/SCN 2000). While the national LBW average is 23 percent; this 
study found an extremely high percentage of LBW infants (58.8%) among women suffering from HDP, and 
about two thirds (62.5%) were also pre-term or premature. LBW was even higher among women suffering 
from severe PE/E (64.5%). These results call for action to adequately control women’s BP throughout e 
pregnancy regardless of underlying pathological factors, in addition to providing adequate nutrition. 
It is now widely accepted that there are two different etiologies of PE/E, differentiated by gestational age 
at onset, frequently described as early onset (EO, <34 weeks gestation) and late onset (LO, ≥34 weeks 
gestation). There are differences in terms of biological markers, clinical manifestation, maternal and 
perinatal outcome, prognosis, and complication (Huppertz 2008, Gomathy et al 2018). EO-PE is the most 
severe clinical variant, occurring in five percent to 20 percent of all PE cases and is associated with fetal 
growth restriction and adverse maternal and neonatal outcomes. LO-PE occurs in about 75 percent to 80 
percent of all PE cases, associated with maternal morbidity but more favorable perinatal outcomes (Madazi 
et al 2018, Sulistyowati et al 2017). Overall EO-PE in this study is 25.3 percent, slightly higher than global 




Special consideration should be given to EO-PE, as it is more severe and life-threatening. Low dose aspirin 
(75mg) is a useful prophylactic, particularly among high risk patients at an early stage compared to LO-PE 
(WHO 2011). Routine prophylactic low dose aspirin (75mg) for women at risk of PE should be encouraged 
and strengthened in Bangladesh. 
Currently, pre-term or premature birth (between 20 to 37 weeks of pregnancy) is the leading cause of death 
among children under five around the world, and a leading cause of disability and ill health later in life. Sub-
Saharan Africa and South Asia account for over 60 percent of pre-term births worldwide (Every Preemie 
Scale 2018). Bangladesh’s national average of pre-term or premature birth is 14 percent, but 26 percent 
for women with HDPs (ibid). This study’s pre-term or premature birth rate is much higher (63.3%), including 
an extremely pre-term or premature rate (<28 weeks) of 4.3 percent among women with severe PE/E. 
Although this study was conducted at a tertiary hospital addressing all emergencies, this rate of pre-term 
or premature delivery among women with HDP seems high, and needs further explanation. One reason for 
this elevated rate could be the small sample size. WHO estimates, using data from 184 countries, rates of 
premature delivery from five percent to 18 percent (WHO 2019, Blencowe et al 2012). These reports do 
not mention any rates among women with HDP, and there are many reasons for pre-term delivery. 
Globally, stillbirth remains a significant public health issue, particularly in developing countries such as 
Bangladesh. Bangladesh is a major contributor to stillbirth rates in South Asia (Lawn et al 2016), with a 
reported stillbirth rate of 20 per 1,000 live births in 2015 (Bhutta et al 2016). Analysis of Bangladesh 
Demographic and Health Surveys data for 2004, 2007, 2011, and 2014 reveal a stillbirth rate of 28 per 
1,000 births. Lack of maternal education, primiparity, and household poverty are considered predictors of 
stillbirth in Bangladesh (Tanvir et al 2015).  
While there is a lack of enough clinical data on stillbirths among women with HDP, this study suggests a 
high stillbirth rate, of 15.3 percent, among women with HDP. A population-based surveillance study 
(n=6,333) in four districts of Bangladesh revealed the three most frequent causes of stillbirth as maternal 
hypertension or eclampsia (15.2%), antepartum hemorrhage (13.7%), and maternal infections (8.9%), with 
a stillbirth rate of 20.4 per 1,000 births (Halim et al 2018). These findings indicate the need for improved 
quality of ANC and intrapartum care. 
This study reveals that quality of care for women experiencing HDP at a tertiary hospital is largely sub-
optimal. UK’s NICE clinical guidelines recommend measuring BP for the first three days after delivery, and 
at least once more before the fifth day, for women with HDP (NICE 2011). While this recommendation was 
followed for 89 percent of women on the first day postnatal, adherence progressively declined over the 
following four days, and by the fifth day BP was not checked in most (84%) women. This huge gap could be 
due, however, in part to lack of documentation of BP measurement.  
Urine albumin analysis was also not performed as recommended. Eleven percent of women were recorded 
as having albumin in their urine on the day of discharge, and if all women were in fact checked upon 
discharge, this figure—an indicator for long term monitoring and follow up of women with HDPs—would likely 
be much higher. These gross omissions or oversights in the care of women with HDPs could be life-
threatening, as adverse cardiovascular events can occur three to five days after delivery due to uncontrolled 
high BP (Payne et al 2016). 
Similar quality of care lapses were identified for anti-hypertensive drug coverage during the immediate 
postnatal period. Overall, 74.7 percent of women with moderate to severe hypertension received anti-
hypertensive treatment immediately following delivery (within 7 days). While 90 percent of women with 
chronic hypertension were recommended to continue anti-hypertensive treatment the first week after 
delivery, among women with PE who required continued anti-hypertensive coverage (BP ≥150/100mmHg), 




with gestational hypertension (33.4%). Besides insufficient management of BP in the immediate postnatal 
period, poor adherence to clinical guidelines was seen in other aspects of care, particularly patient 
counseling.  
It is recommended that all women with PE, severe PE/E should receive thromboprophylaxis for four weeks 
after delivery (RCOG, NICE 2011), however, in this study no woman with PE received thromboprophylaxis, 
even for one day. This is of particular concern considering these women were attending a tertiary and 
teaching hospital, where high quality care is expected. 
It is important to follow and monitor women with HDP to identify patterns of morbidities and any imminent 
complications (Slvaggi et al 1988). Although HDPs (except chronic hypertension) should typically resolve 
six to eight weeks after delivery, there is increasing evidence that hypertension does not resolve in all cases, 
remaining persistent and chronic in some (Garovic and August 2013, Craici et al 2008, McDonald et al 
2008, Sibai et al 1986, Kaze et al 2014). In this study, hypertension persisted up to one year after delivery 
in a number of women (1 out of 4) with gestational hypertension, PE (1 out of 2), and severe PE/E (3 out of 
14). Similarly, other aspects of metabolic functions also persisted in these women for one year, such as 
albuminuria (3.1%), high serum creatinine (6.3%), glucose intolerance, increased liver enzymes (Alanine 
and Aspartate transaminases), serum cholesterol, and triglycerides.  
These findings indicate, as most guidelines specify, that all women with HDPs should be provided 
comprehensive medical reviews that include routine screening for metabolic syndrome, as well as referrals.  
Limitation 
The women who continued follow up care in this study are likely those with worse health outcomes, which 
compelled their continuation of care, than the other women with HDP recruited for the study who did not 
continue their care at DMCH. This likelihood thus provides a study sample not fully representative of the 






Conclusion and Recommendations 
The following conclusions and recommendations—for health care providers, public health experts, policy-
makers, health administrators, and developmental partners in Bangladesh—emerged from this study of 
service provision to women with HDPs: 
• Gaps in PNC are evident including clinical assessments, laboratory evaluations, patient counseling, 
and follow ups. Standard operating procedures (SOPs) for PNC should be developed including 
management of women with HDPs, and made widely available to obstetricians, nurses, and midwives 
who provide services to pregnant women. 
• Challenges in women’s postnatal health-seeking behaviors need to be addressed. Women with 
pregnancy and postnatal complications, as well as their families, require relevant and understandable 
information enabling their awareness and understanding of potential consequences for their future 
health, and thus the necessity of follow up consultations. Presently, counseling about potential future 
health complications is negligible. Health facilities and staff must find effective means of ensuring 
women’s return to facilities for PNC and follow up, and increase efficiencies in facilities so service 
providers can provide effective counseling. 
• Blood pressure is either not routinely measured, or measured and not documented; service providers 
treating pregnant women should be aware of the importance of routine BP measurement and 
monitoring of women, including after delivery, and its documentation. Routine monitoring and 
documentation should include urine albumin as well. 
• All service providers should be aware that HDP does not necessarily resolve following delivery, and 
that all women with HDP must be monitored until resolution of their hypertension is confirmed and 
documented, to avoid any further complications. Screening for development of metabolic syndromes 
following PE-complicated pregnancies should be routine by service providers.  
• Early detection of HDP and its careful management are essential, and it is recommended that all 
pregnant women are screened for PE after 20 weeks of pregnancy. 
• Pre-term and LBW infant delivery were extremely common, and all women with HDP should be aware 
of the nearest hospital with neonatal support for delivery.  
• Women with HDP were rushed or referred to DMCH from a number of districts surrounding Dhaka, 
which indicates inefficiencies and lack of capacities at lower levels as well as in many districts of the 
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Clinical and Laboratory Parameters Assessed 
Examples of prescribed ongoing care that were monitored and evaluated in this study: 
• Measurement of BP daily for 2 days after birth for women with chronic and gestational hypertension 
and measurement of BP 4 times a day for first 2 days for women with PE. 
• Measurement of BP, at least, once between day 3 and 5 after birth in women with all forms of 
hypertensive disorders in pregnancy. 
• For women with PE, assess if they were asked about severe headache or epigastric pain any time BP 
was measured. 
• If BP after birth were less than 150/100mmHg in women with HDPs. 
• Continuation of anti-hypertensive treatment in appropriate cases. 
• If women with gestational hypertension and pre-eclampsia who remained on anti-hypertensive 
treatment 2 weeks after discharge from hospital were offered a medical review 
• If women with any form of HDPs were offered a medical review at between 6 to 8 weeks postpartum. 
• If women with gestational hypertension and pre-eclampsia still required anti-hypertensive treatment 
after 6 to 8 weeks after birth 
• If women with PE were transferred to community care (discharged) when there were no symptoms of 
PE, BP was less than 150/100mmHg and blood test results were stable or improving. 
• If women who have suffered from pre-eclampsia had their platelets, transaminase, and serum 
creatinine measured 48 to 72 hours after delivery 
• If women with PE had their urine protein estimated using urine dipsticks at 6 to 8 weeks after birth. If 
women with persistent proteinuria had a further review done at 3 months after birth to assess kidney 
function for possible referral for specialist kidney assessment. 
• If women who have suffered from pre-eclampsia were advised to achieve and keep a Body Mass Index 
(BMI) within a health range (18.5 - 24.9kg/m2) before the next pregnancy. 
Examples of medical complications that were monitored for, and evaluated in women who have suffered 
from HDPs included: 
• Hypertension and its complications (stroke, cardiovascular disease) 
• Presence or absence of modifiable cardiovascular risk factors such as high blood glucose, cholesterol 
and triglycerides.  
• Long-term risk of end stage kidney disease (urea and creatinine) 
• Increase risk or occurrence of thrombosis 
